Cargando…

New Approaches to the Treatment of Chronic Hepatitis B

The currently recommended treatment for chronic hepatitis B virus (HBV) infection achieves only viral suppression whilst on therapy, but rarely hepatitis B surface antigen (HBsAg) loss. The ultimate therapeutic endpoint is the combination of HBsAg loss, inhibition of new hepatocyte infection, elimin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alexopoulou, Alexandra, Vasilieva, Larisa, Karayiannis, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601587/ https://www.ncbi.nlm.nih.gov/pubmed/33019573 http://dx.doi.org/10.3390/jcm9103187

Ejemplares similares

Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals
por: Alexopoulou, Alexandra, et al.
Publicado: (2015)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Bacterial translocation markers in liver cirrhosis
por: Alexopoulou, Alexandra, et al.
Publicado: (2017)

Mechanisms of sarcopenia in liver cirrhosis and the role of myokines
por: Geladari, Eleni, et al.
Publicado: (2023)

Chronic Hepatitis B Infection: New Approaches towards Cure
por: Ogunnaike, Mojisola, et al.
Publicado: (2023)

Serum Hepatitis B Surface Antigen Levels and Their Utility as a Predictor of Sustained Virological Response After Antiviral Treatment
por: Karayiannis, Peter
Publicado: (2012)

The Epigenetic Control of Hepatitis B Virus Modulates the Outcome of Infection
por: Koumbi, Lemonica, et al.
Publicado: (2016)

New approaches in the management of chronic hepatitis B: role of tenofovir
por: Reijnders, Jurriën GP, et al.
Publicado: (2009)

The significance of platelet microparticles in patients with chronic hepatitis C and their association with antiviral treatment and smoking
por: Kanellopoulou, Theoni, et al.
Publicado: (2016)

Interleukin-17A and B-cell activating factor in chronic hepatitis C patients with or without asymptomatic mixed cryoglobulinemia: effects of antiviral treatment and correlations with vitamin D
por: Konstantinides, Polydoros, et al.
Publicado: (2018)

The Presence of Myosteatosis Is Associated with Age, Severity of Liver Disease and Poor Outcome and May Represent a Prodromal Phase of Sarcopenia in Patients with Liver Cirrhosis
por: Geladari, Eleni, et al.
Publicado: (2023)

New Biomarkers of Chronic Hepatitis B
por: Mak, Lung-Yi, et al.
Publicado: (2019)

Oral Conditions Associated with Hepatitis C Virus Infection
por: Alavian, Seyed-Moayed, et al.
Publicado: (2013)

Recent challenges facing patients with preexisting chronic liver disease in the era of the COVID-19 pandemic
por: Mani, Iliana, et al.
Publicado: (2021)

Bacterial DNA is a prognostic factor for mortality in patients who recover from spontaneous bacterial peritonitis
por: Mani, Iliana, et al.
Publicado: (2021)

A Practical Approach to Management of Chronic Hepatitis B
por: Hu, Ke-Qin
Publicado: (2005)

New treatments for chronic hepatitis C
por: Jang, Jae Young, et al.
Publicado: (2010)

Advances in new antivirals for chronic hepatitis B
por: Tang, Yanhua, et al.
Publicado: (2022)

The role of entecavir in the treatment of chronic hepatitis B
por: Dimou, Evangelini, et al.
Publicado: (2007)

Therapeutic vaccination for treatment of chronic hepatitis B
por: Cargill, Tamsin, et al.
Publicado: (2021)

Virological Treatment Monitoring for Chronic Hepatitis B
por: Loggi, Elisabetta, et al.
Publicado: (2022)

New perspectives of biomarkers for the management of chronic hepatitis B
por: Lin, Chih-Lin, et al.
Publicado: (2016)

Hepatitis B viral replication influences the expression of natural killer cell ligands
por: Koumbi, Lemonica, et al.
Publicado: (2016)

Safety and efficacy of entecavir for the treatment of chronic hepatitis B
por: Osborn, Melissa
Publicado: (2011)

Safety and efficacy of telbivudine for the treatment of chronic hepatitis B
por: Osborn, Melissa K
Publicado: (2009)

Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections(†)
por: De Clercq, Erik, et al.
Publicado: (2010)

The treatment of chronic hepatitis B: Focus on adefovir-like antivirals
por: Tillmann, Hans Ludger
Publicado: (2008)

Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2023)

Prevention and Management of Chronic Hepatitis B
por: Bhat, Mamatha, et al.
Publicado: (2014)

Endpoints and New Options for Treatment of Chronic Hepatitis D
por: Lok, Anna S., et al.
Publicado: (2021)

Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine
por: Colombatto, Piero, et al.
Publicado: (2022)

Meeting the Challenge of Eliminating Chronic Hepatitis B Infection
por: Revill, Peter A., et al.
Publicado: (2019)

New treatments for genotype 1 chronic hepatitis C – focus on simeprevir
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B
por: Watanabe, Takehisa, et al.
Publicado: (2021)

The New Era of Interferon-Free Treatment of Chronic Hepatitis C
por: Solbach, Philipp, et al.
Publicado: (2015)

Demographic changes of hepatitis B virus infection in Iran for the last two decades
por: Mohaghegh Shelmani, Hamid, et al.
Publicado: (2017)

A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B
por: Hanif, Hira, et al.
Publicado: (2020)

Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management
por: Vachon, Alicia, et al.
Publicado: (2021)

Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck
por: Kosinska, Anna D., et al.
Publicado: (2014)

Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy
por: Ogawa, Eiichi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_r5aplhi9993naqc3g81pa9n66r